164 related articles for article (PubMed ID: 36982528)
21. The JNK, ERK and p53 pathways play distinct roles in apoptosis mediated by the antitumor agents vinblastine, doxorubicin, and etoposide.
Brantley-Finley C; Lyle CS; Du L; Goodwin ME; Hall T; Szwedo D; Kaushal GP; Chambers TC
Biochem Pharmacol; 2003 Aug; 66(3):459-69. PubMed ID: 12907245
[TBL] [Abstract][Full Text] [Related]
22. Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma.
Sun C; Wang L; Huang S; Heynen GJ; Prahallad A; Robert C; Haanen J; Blank C; Wesseling J; Willems SM; Zecchin D; Hobor S; Bajpe PK; Lieftink C; Mateus C; Vagner S; Grernrum W; Hofland I; Schlicker A; Wessels LF; Beijersbergen RL; Bardelli A; Di Nicolantonio F; Eggermont AM; Bernards R
Nature; 2014 Apr; 508(7494):118-22. PubMed ID: 24670642
[TBL] [Abstract][Full Text] [Related]
23. A spoonful of sugar makes the melanoma go: the role of heparan sulfate proteoglycans in melanoma metastasis.
O'Connell MP; Weeraratna AT
Pigment Cell Melanoma Res; 2011 Dec; 24(6):1133-47. PubMed ID: 21978367
[TBL] [Abstract][Full Text] [Related]
24. Trichostatin A, a histone deacetylase inhibitor, induces synergistic cytotoxicity with chemotherapy via suppression of Raf/MEK/ERK pathway in urothelial carcinoma.
Lin WC; Hsu FS; Kuo KL; Liu SH; Shun CT; Shi CS; Chang HC; Tsai YC; Lin MC; Wu JT; Kuo Y; Chow PM; Liao SM; Yang SP; Hong JY; Huang KH
J Mol Med (Berl); 2018 Dec; 96(12):1307-1318. PubMed ID: 30288546
[TBL] [Abstract][Full Text] [Related]
25. β
Baltes F; Pfeifer V; Silbermann K; Caspers J; Wantoch von Rekowski K; Schlesinger M; Bendas G
Biochim Biophys Acta Mol Cell Res; 2020 May; 1867(5):118663. PubMed ID: 31987794
[TBL] [Abstract][Full Text] [Related]
26. Heparan sulfate proteoglycans in beta cells provide a critical link between endoplasmic reticulum stress, oxidative stress and type 2 diabetes.
Dhounchak S; Popp SK; Brown DJ; Laybutt DR; Biden TJ; Bornstein SR; Parish CR; Simeonovic CJ
PLoS One; 2021; 16(6):e0252607. PubMed ID: 34086738
[TBL] [Abstract][Full Text] [Related]
27. Cancer cell exosomes depend on cell-surface heparan sulfate proteoglycans for their internalization and functional activity.
Christianson HC; Svensson KJ; van Kuppevelt TH; Li JP; Belting M
Proc Natl Acad Sci U S A; 2013 Oct; 110(43):17380-5. PubMed ID: 24101524
[TBL] [Abstract][Full Text] [Related]
28. Acute UV irradiation increases heparan sulfate proteoglycan levels in human skin.
Jung JY; Oh JH; Kim YK; Shin MH; Lee D; Chung JH
J Korean Med Sci; 2012 Mar; 27(3):300-6. PubMed ID: 22379342
[TBL] [Abstract][Full Text] [Related]
29. Combinatorial treatments that overcome PDGFRβ-driven resistance of melanoma cells to V600EB-RAF inhibition.
Shi H; Kong X; Ribas A; Lo RS
Cancer Res; 2011 Aug; 71(15):5067-74. PubMed ID: 21803746
[TBL] [Abstract][Full Text] [Related]
30. Transient activation of EGFR/AKT cell survival pathway and expression of survivin contribute to reduced sensitivity of human melanoma cells to betulinic acid.
Qiu L; Wang Q; Di W; Jiang Q; Schefeller E; Derby S; Wanebo H; Yan B; Wan Y
Int J Oncol; 2005 Sep; 27(3):823-30. PubMed ID: 16077934
[TBL] [Abstract][Full Text] [Related]
31. Differential activity of MEK and ERK inhibitors in BRAF inhibitor resistant melanoma.
Carlino MS; Todd JR; Gowrishankar K; Mijatov B; Pupo GM; Fung C; Snoyman S; Hersey P; Long GV; Kefford RF; Rizos H
Mol Oncol; 2014 May; 8(3):544-54. PubMed ID: 24476679
[TBL] [Abstract][Full Text] [Related]
32. Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib.
Acquaviva J; Smith DL; Jimenez JP; Zhang C; Sequeira M; He S; Sang J; Bates RC; Proia DA
Mol Cancer Ther; 2014 Feb; 13(2):353-63. PubMed ID: 24398428
[TBL] [Abstract][Full Text] [Related]
33. Aberrant modulation of ribosomal protein S6 phosphorylation confers acquired resistance to MAPK pathway inhibitors in BRAF-mutant melanoma.
Gao MZ; Wang HB; Chen XL; Cao WT; Fu L; Li Y; Quan HT; Xie CY; Lou LG
Acta Pharmacol Sin; 2019 Feb; 40(2):268-278. PubMed ID: 29777202
[TBL] [Abstract][Full Text] [Related]
34. Heparan Sulfate Proteoglycans (HSPGs) Serve as the Mediator Between Monomeric Tau and Its Subsequent Intracellular ERK1/2 Pathway Activation.
Song L; Oseid DE; Wells EA; Coaston T; Robinson AS
J Mol Neurosci; 2022 Apr; 72(4):772-791. PubMed ID: 35040015
[TBL] [Abstract][Full Text] [Related]
35. PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas.
Lu H; Liu S; Zhang G; Bin Wu ; Zhu Y; Frederick DT; Hu Y; Zhong W; Randell S; Sadek N; Zhang W; Chen G; Cheng C; Zeng J; Wu LW; Zhang J; Liu X; Xu W; Krepler C; Sproesser K; Xiao M; Miao B; Liu J; Song CD; Liu JY; Karakousis GC; Schuchter LM; Lu Y; Mills G; Cong Y; Chernoff J; Guo J; Boland GM; Sullivan RJ; Wei Z; Field J; Amaravadi RK; Flaherty KT; Herlyn M; Xu X; Guo W
Nature; 2017 Oct; 550(7674):133-136. PubMed ID: 28953887
[TBL] [Abstract][Full Text] [Related]
36. RNAi-mediated downregulation of CDKL1 inhibits growth and colony-formation ability, promotes apoptosis of human melanoma cells.
Song Z; Lin J; Sun Z; Ni J; Sha Y
J Dermatol Sci; 2015 Jul; 79(1):57-63. PubMed ID: 25920913
[TBL] [Abstract][Full Text] [Related]
37. Paclitaxel induces prolonged activation of the Ras/MEK/ERK pathway independently of activating the programmed cell death machinery.
Okano J ; Rustgi AK
J Biol Chem; 2001 Jun; 276(22):19555-64. PubMed ID: 11278851
[TBL] [Abstract][Full Text] [Related]
38. The transcription cofactor c-JUN mediates phenotype switching and BRAF inhibitor resistance in melanoma.
Ramsdale R; Jorissen RN; Li FZ; Al-Obaidi S; Ward T; Sheppard KE; Bukczynska PE; Young RJ; Boyle SE; Shackleton M; Bollag G; Long GV; Tulchinsky E; Rizos H; Pearson RB; McArthur GA; Dhillon AS; Ferrao PT
Sci Signal; 2015 Aug; 8(390):ra82. PubMed ID: 26286024
[TBL] [Abstract][Full Text] [Related]
39. Heparan sulfate proteoglycan expression in human lung-cancer cells.
Nackaerts K; Verbeken E; Deneffe G; Vanderschueren B; Demedts M; David G
Int J Cancer; 1997 Jun; 74(3):335-45. PubMed ID: 9221815
[TBL] [Abstract][Full Text] [Related]
40. Heparan sulfate-dependent ERK activation contributes to the overexpression of fibrotic proteins and enhanced contraction by scleroderma fibroblasts.
Chen Y; Leask A; Abraham DJ; Pala D; Shiwen X; Khan K; Liu S; Carter DE; Wilcox-Adelman S; Goetinck P; Denton CP; Black CM; Pitsillides AA; Sarraf CE; Eastwood M
Arthritis Rheum; 2008 Feb; 58(2):577-85. PubMed ID: 18240216
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
